Art Exhibition essays

Art Exhibition essays The art gallery manager was surprised when he was asked to book the gallery for a solo exhibition by a twelfth grader, me. He wavered to give his assent as the gallery only exhibited established artists works. After a little persuasion he demanded to see my artwork - they were sketches and paintings. I already had a few works of mine, which I handed over to him. All of a sudden he was all excited, time and again praising the work. Next movement the dates and the rest were finalized. From then till the closing ceremony of my exhibition the events were all challenging exciting and above all mostly satisfying. It took me some time to realize that mounting and framing my paintings and booking an art gallery wasn't all that was to be done. There were a whole lot of things to be done behind the scenes. First thing was selecting about 50 works to be put up in the exhibition. After that came the brochure printing. The brochure had to have a few comments by other critics or artists. I showed my work to two established artists, one being a famous playwright, making folk dramas and the other a renowned painter. Both of them recommended me very well. The design and the layout of the brochure were another laborious job. Things like the background colour, the cover painting font size, colour, inside sketches and the written matter. The layout of the brochure was supposed to be appealing and enticing. The challenge of the designing was a big thing as, this is the fore most important thing that kindles an interest in people to come and see the exhibition. Preparation of the guest list caught my attention next. A guest list of around 350 people consisting mainly of artists was created. My mother was of great help, being an artist herself. Even publicity was a part of this whole action. Advertising in the newspaper, putting up posters needed a lot of planning; a lot of experienced people helped me out with the tasks. Last of all my friends and m ...

An Explanation of the Truman Doctrine

An Explanation of the Truman Doctrine The Truman Doctrine was a key part of the Cold War, both in how this conflict of posturing and puppets began, and how it developed over the years. The doctrine was policy to support free peoples who are resisting attempted subjugation by armed minorities or by outside pressures, and announced on March 12th, 1947 by US President Harry Truman, making the doctrine US government policy for decades. The Start of the Truman Doctrine The doctrine was dreamed up in response to crises in Greece and Turkey, nations which Americans believed were in danger of falling into the Soviet sphere of influence. The US and the USSR had been in alliance during the Second World War, but this was to defeat a common enemy in the Germans and the Japanese. When the war ended and Stalin was left in control of Eastern Europe, which he had conquered and intended to subjugate, the US realized the world was left with two superpowers, and one was as bad as the Nazis they had just defeated and far stronger than before. Fear was mixed with paranoia and a little bit of guilt. A conflict was possible, depending on how both sides reacted... and they produced one. While there was no realistic way to free Eastern Europe from Soviet domination, Truman and the US wanted to stop any further countries falling within their control, and the presidents speech promised monetary aid and military advisors to Greece and Turkey to stop them buckling. However, the doctrine was not just aimed at these two, but expanded worldwide as part of the Cold War to cover assistance to all nations threatened by communism and the Soviet Union, involving the US with western Europe, Korea, and Vietnam among others. A major part of the doctrine was the policy of containment. The Truman Doctrine was developed in 1950 by NSC-68 (National Security Council Report 68) which assumed the Soviet Union was trying to spread its power across the whole world, decided that the US should stop this and advocated a more active, military, policy of containment, fully abandoning previous US doctrines like Isolationism. The resulting military budget rose from $13 billion in 1950 to $60 billion in 1951 as the US prepared for the struggle. Good or Bad? What did this mean, in practice? On the one hand, it meant the US involving themselves in every region of the world, and this has been described as a constant battle to keep freedom and democracy alive and well where they are threatened, just as Truman announced. On the other, it is becoming increasingly impossible to look at the Truman doctrine without noticing the terrible governments who were supported, and the highly questionable actions taken by the free west, in order to support opponents of the Soviets.

Is democracy necessary to protect universal human rights Essay - 1

Is democracy necessary to protect universal human rights - Essay Example This leads us to the last premise, democracy and human rights are closely interlinked to a point that they strengthen each other and that they are inseparable. Meaning, each is vital to the other. If human rights define democracy, democracy facilitates the realization of human rights. In short, the necessity of democracy for the protection of universal human rights resides on the very principles, process, and nature of democracy. To explain further, each premise is discussed below. Premise 1: Democracy upholds the principles of universal human rights. To explain this premise entails a brief discussion on the concepts of democracy and human rights, because this premise rests its assertion on the very principles that these two concepts uphold. Human rights Donnelly (2003, 10) explains, ‘are literally, the rights that one has simply because one is human’. As such, he characterizes human rights to be equal, inalienable and universal. Meaning human rights are applicable to ev ery human being regardless of color, sex, and creed. It is absolute that it cannot be denied from any one. In fact to him, even those who behave badly are entitled to these rights since no one can stop one from being human. This perhaps is due to the fact that no man is perfect. Every one of us at one time or another in our lives commits mistakes. This however should not be misconstrued as a justification for violating one’s right, because as always said, in every right there is a corresponding responsibility. In other words, one’s exercise and enjoyment of his/her right should not obstruct nor limit another’s exercise of his/her right. A classic example of this is the exercise of one’s right to freedom of speech/expression. As Amnesty International states: your right to freedom of speech is limited by your responsibility not to say untrue things which will degrade another person and abuse their right to dignity and good reputation’ (cited in Sprin g 2000, 70). Meaning, one cannot make use of his/her right to freedom of expression by committing oral defamation or slander. This clearly illustrates that human rights should be exercise with respect for the rights of others. Thus human rights must reside on facts and truths. Therefore, human rights are rights that recognize the dignity which set human beings far above from other forms of animals, that violating any of it is a direct assault to human dignity. However, human rights unless justified and accepted would be useless. In practice today, human rights are justified by a constitution or declaration (Parsons 2004, 32-33). An example of which are the Universal Declaration of Human Rights and international treatises such as the International Covenant on Civil and Political Rights, 1966; the International Covenant on Economic, Social and Cultural Rights, 1966; the Convention on the Rights of the Child, 1989; the Convention on the Prevention and Punishment of the Crime of Genocid e, 1948; the International Convention on the Elimination of All Forms of racial Discrimination, 1965; the Convention against Torture and Other Cruel, Inhuman or degrading Treatment or Punishment, 1984; and the Convention on the Elimination of All Forms of Discrimination against Women, 1979 (United Nations 2003). Notably though, these human rights instruments could only be possible under democracy. Why is it so, necessitates our understanding of democracy. Defining democracy is not simply an academic exercise but

Financial accounting (Asset, liability, revenue, expense and sale) Essay

Financial accounting (Asset, liability, revenue, expense and sale) - Essay Example Further those are classified as tangible or intangible assets. Use of fixed assets is written off to profit and loss account as depreciation. Liabilities are of two types, namely current liabilities and non- current liabilities. Liabilities whose obligation to pay arise within a period of twelve months or in a business cycle are called current liabilities. These are classified in balance sheet on liabilities side as ‘current liabilities’ and also include the current obligations (arising within 12 months) of long term liabilities. It may also be shown as deduction from current assets in order to calculate net current assets. Long term liabilities or non- current liabilities are those are due to be paid beyond a period of twelve months or a business cycle. These are shown separately than current liabilities on liability side of balance sheet. Expenses: Expenses generally result from increases in liabilities or decreases in assets. For example rent for use of business premises increases the current liabilities and thus results in expenses. Expenses are deducted from total revenue or income in an income statement or profit and loss account in order to compute profits or losses during an accounting period. Expenses may be revenue expenditure or non- revenue expenditure Revenue expenses are used to compute profits or losses of the business. Non- revenue expenses are generally added to assets in respect of which those are incurred. Sale: Sale of goods takes place on transfer of ownership to the buyer and receipt of value or claim to the sales value of such goods. Sales are recognized as revenue from regular business of entity. The goods dealt in are those in the regular course of business of the entity. Sale is treated as revenue or income in the profit and loss account for purpose of calculation of profit or loss earned during the accounting period. Sales that are

The Weaknesses and impact of Education administration Essay

The Weaknesses and impact of Education administration - Essay Example As a result, there have been various policies, as well as reforms that have been advocated so as to improve education and foster economic capacity. All these efforts are an acknowledgement of the existent education disparities. However, there are still a lot that is needed to realize the potential. In some cases, education has been presented to serve a purpose that is opposite the intended one. According to CORI Justice, Education can be a powerful force in counteracting inequality and poverty but in many ways, the present education system has quite the opposite effect' (socio-Economic Review 2008). As far education disparities along the racial lines are concerns, the achievements between the native and the non-native populations is widely inferred. Indeed, it is agreeable that there have been disparities between the aboriginal and the non-aboriginal groups for quite some time. These disparities have been described as the legacy of colonialism. Colonization processes are associated w ith profound consequences on the colonized societies. Colonial legacies, which now come in the form of government policies, have seen individuals disperse from the tribal and clan inclinations. The eventuality of this has been the continuous fragmentation of the cultures belonging to the aboriginal people. There have been concerns that the fragmentation of culture and the struggle to adapt to the new way of life has been accompanied by social, as well as economic instability. As such, the disintegration of

Causes, Effects And Implications Of Sibling Incest

Causes, Effects And Implications Of Sibling Incest This literature review focuses on research that is related to sibling incest and discusses the causes, effects and implications that sibling incest has on the victim, perpetrator and the family. It focuses on the types of research that is conducted and the weaknesses and strengths of these studies. It also discusses further implications and suggestions for future research in regards to sibling incest. It is meant as a review of the types of research and how this affects our views on sibling incest and ways that we can improve future research to help those that are victims, perpetrators and impacted by sibling incest. Sibling Incest is a huge taboo in the US and an issue that is largely dismissed as something that is not experienced by the general population and occurs only in a very small amount of cases. After reading each of these articles, it has become clear that there is a significant lack of research regarding this particular form of family abuse. Much of what has been researched seems to contradict each other and are questions regarding this hidden taboo continue to go unanswered. When most people in the US think of incest, specifically sibling incest, they seem perplexed as to what causes this desire in people and how this plays out in a family. Sibling incest seems to be considered one of the highest forms of abuse within a family and needs to be researched so that we may begin to understand the full impacts this has on individuals and families. By researching and understanding this abuse more thoroughly we might be able to prevent future incest cases and help victims and perpetrators re cover from such a violent form of abuse. We might also be able to come to understand the full impacts of sibling incest and if our views as a country and our taboo against it holds true. Does sibling incest violate such basic psychological views and trusting relationships that might damage the victim more than any other type of family abuse? Thompson discussed why incest between siblings needs to be studied more than any other area (2009). The author described the sibling relationship in regards to incest and the effects the incest has on the victim and the family as a whole. Thompson sheds light on the families of sibling incest relationships and different theories that can begin to explain the family system and family response upon disclosure of the abuse. The author examines how blaming plays a part in the reactions to incest disclosure by the family, and how this affects the health and wellbeing of the victim. Thompson describes different coping mechanisms and the effectiveness of group therapy in the lives of incest victims. The author briefly discusses different theoretical frameworks that might aid in work dealing with female victims of incest. Thompson focuses on family systems theory and the relationships within the family. A group model is mentioned as a successful way to work through incest trauma and develop healthy coping strategies. Short-term and long-term group models are discussed in their benefits and disadvantages that each provide (Thompson, 2009). Kissing Your Sister The article Kissing Your Sister summarizes a study performed by three evolutionary psychologists, Debra Lieberman, John Tooby, and Leda Cosmides. The study sheds light as to what makes people avoid incest relations. The study was performed on 600 people and investigated their family histories and relationships. The study suggested that there are two main things that trigger us to avoid sexual relationships with our siblings. These triggers are the amount of time that the person spends with the childs mother at a young age and the amount of time the two spend living in the same house. According to the authors, these trigger two evolutionary processes that are beneficial to the survival of humans. Altruism and aversion to incest help individuals to survive by getting along and avoiding possible malfunctions in reproduction. Sibling Incest: Reports from 41 Survivors In the article, the authors discussed a study that was performed with 41 adults who experienced sibling incest. The research was done due to a significant lack of previous research in this specific area. Included in the study were men and women, perpetrators and victims. The sample consisted mostly of Caucasian working-class women with a mean age of 39 years old. They asked open-ended and closed-ended questions regarding the abuse, who started it, the duration, and disclosure. The report results reported several findings. It suggested that the average age difference was around 4 years with victims being, on average, around age 7 at onset and age 13 at the end of the abuse. The questions investigated several issues included who initiated the abuse and the threat of violence that is placed on the individual. The authors also investigated other sexual abuse experienced by the participants and the environment of the family, including any physical, emotional, and/or sexual abuse experienc ed with other family members and non-family members. Sibling Incest within Violent Families: Children under 12 Seeking Nurture In the article, the author investigates possible causes that might lead to sibling incest including violent homes, neglect, and a need for love and nurture. The author suggests that violence in the home may influence a childs sexual identity and possibly influence the desire for incest. The author defines violent families, the concept of nurture, and sibling incest in order to create a picture of how they might interact and influence each other. The author uses anecdotal evidence to support her views that family violence may lead to a different sexual identity in the child and sibling incest desires. The author explores the process children exposed to violent families might go through. She recognizes the need for connection, comfort and nurture that the child has and suggests that they begin to look for this emotional connection in their siblings. She investigates the sexual progress and exploration that a child goes through from birth to adolescence and how this might be affected by family violence. The author discusses the possible effects of shame and how this might make a child more vulnerable to sibling incest. Findings of each study Sibling Incest: A model for group practice with adult female victims of brother-sister incest. Thompson argues that a long-term group model is best used when working with incest victims. Thompson ends the article pushing for a broader approach when investigating the lives and trauma of incest victims, looking at the way family dynamics and interactions play a part in leading to incest. Thompson recommends group therapy as a way to help victims feel understood and work through their coping skills as a group. Kissing Your Sister The authors interpret their results from their study on sibling incest to suggest that the amount of time the potential incest partner spent with you in the same roof and being raised by the same mother, predict the likelihood of incest behavior. The more time the stepsibling or sibling does spend in these conditions increase the likelihood that you will avoid incest acts. They also suggest that women are more likely to avoid sibling incest possibly due to the desire to reproduce healthy offspring. The authors suggest that aversion to sibling incest is strongest among siblings of the opposite sex. (Lieberman, Tooby, Cosmides, pg. 1) Sibling Incest: Reports from 41 Survivors The authors in this study were led to believe that the average age difference between perpetrators and victims was 4 years with the most cases of sibling incest experiences including fondling and having the siblings genitals rubbed on the subjects body. The study suggests that a majority (68.3%) of participants were coerced, threatened or bribed in order to force cooperation. (pg. 9) It suggested that more male participants believed the sexual experience was consensual. It also suggested that more abuse ended when the perpetrator left home, versus the victim. The majority of participants perceived themselves to be emotionally abused by being ridiculed, degraded or put down, emotionally neglected, or threatened with abuse. (pg. 10) The researchers discovered that disclosure of sexual abuse occurred almost rarely. The majority of participants also reported having sexual experiences with other family members. The study concluded that sibling incest can be long-lasting and frequently ent ails intercourse. In most cases the sexual behavior was coerced in some way. Parents were seldom aware of the abuse while it was occurring, and factors other than disclosure most often led to the incest ending. (pg. 13). Sibling Incest within Violent Families: Children under 12 Seeking Nurture According to the author, the effects of sibling incest can be traumatizing as the individual enters adulthood. The author believes as a result of her anecdotal evidence and researching thoughts on sexual exploration throughout childhood development, that the childs interpretation of sexual exploration might be altered due to the abuse and the childs search for another form of nurture in their environment. As the child develops their views on this will alter, in which case they might view their incest acts as disgusting and no longer normal, thus the adult undergoes significant psychological distress. The author suggests that according to the determinants model, a lack of social support and parental availability will leave the child at high risk for sibling incest, both as a perpetrator and victim. Strengths/Weaknesses of each study In the article Sibling Incest: Reports from 41 Survivors, there are so many elements that skew the findings of the researchers. First, the researchers interviewed both perpetrators and victims, making the title of the article very misleading. By interviewing perpetrators as well as victims, they are skewing the data to represent either higher or lower percentages in certain areas. The age difference between perpetrators and victims was skewed because they used all participants data as representing of the victim, and their counterpart as representing of the perpetrator, even though there were several individuals in the study that reported initiating the abuse. Several other misinterpretations of this data might have led to skewed findings and misunderstandings of sibling incest. Sibling Incest within Violent Families: Children under 12 Seeking Nurture presents some good suggestions and possible ideas on what might cause some forms of sibling incest. It presents good anecdotal evidence that might lead to very good research studies that will investigate this correlation in more depth. However, the anecdotal evidence and the mere opinions of the author are not enough to come to any conclusions about the correlation between family violence and sibling incest. It isnt enough to change therapy, prevention, and intervention in regards to sibling incest. These types of articles are great gateways that lead to further investigations of relationships and causes of many types of family violence and continue to be the start of research that hasnt been investigated yet. Conclusion It is clear that there needs to be much more researched in regards to sibling incest in order to understand the full dynamics and implications of this violation upon an individual. The articles that are mentioned above begin to address these issues, some of which actually addressed possible implications that sibling incest has on individuals. However, most of the research was targeted at causes of sibling incest. They all came to similar conclusions such as the perpetrator is generally about four years older than the victim. The only article that seemed to address the implications of abuse on individuals was Sibling Incest: Reports from 41 Survivors, and this even was very brief and concise. They suggested that victims might feel a sense of distrust towards the opposite sex as adults and feel uncomfortable in sexual relationships. Most studies performed open-ended and close-ended questions on adults that had experienced sibling incest as children. Thompson describes different ways to help victims cope with the abuse as adults by using group therapy and teaching coping mechanisms. The implications that these studies hold on further research of sibling incest are significant. Further research should be used to perform different types of studies and experiments including long-term studies. This becomes a challenge when usually sibling incest is not disclosed until the victim is an adult and much time has passed since the abuse. We should also focus our studies to discover exactly how sibling incest might impact the victims and the families throughout the lifetime and in the next generation. Although some of the research examined was thorough, it is important that we continue research on this subject matter in order to become confident of the causes and understand the family situations that might lead to abuse. Since some of the evidence is contradictory, it would be helpful to gain more insight with better designed studies and larger sample sizes. I hope that some of these articles encourage more research to be done on such a difficult topic to understand as sibling incest.

Key Features of Lavertys Father and Son :: Bernard Mac Laverty

Describe the key features if a short story you have enjoyed, saying what has impressed you most about it. â€Å"Father and Son† is written by Bernard Mac Laverty. One of the main themes of â€Å"Father and Son† is the breakdown of a family relationship. A main feature of â€Å"Father and Son† is repetition and this feature helps to show the relationship between the father and son. Another feature is tones, each character reveals different examples of tones. The son has an aggressive tone, while the father has a caring and almost frail tone. These key features help the reader to enjoy the short story â€Å"Father and Son†. â€Å"Father and Son† helps to highlight the theme of family breakdown after the boss of a family member. This can be shown by â€Å"I love him so much it hurts but he won’t talk to me†. This shows the father tries to keep a close bond between them both. However, the son wants to create a large distance between them this maybe because of him growing up and wanting to become an adult. These helps most readers to relate to the characters and enjoy this book as most readers have been teenagers or are parents and can sympathize with their situation. This father and son relationship is very strained. A previous incident it is suggested that the son was close to death. The reader can pick this up with the quotation â€Å"Look, Da, I have not touched the stuff since I came back†. This helps to explain why the father has became so needy to be a part of his son’s life, because they have already lost a family member and almost losing his son scared him deeply, however this incidentally pushes his son further away. The father cares greatly for his son. The writer helps us to understand this by not naming the son. This encourages the repetition of â€Å"my son†, which shows the pride and love this father has for his son. This helps us to comprehend the pain the father feels about the distance in his relationship with his son. The pleasure of understanding and empathizing with the father helps us to enjoy â€Å"Father and Son†. The tone is very important in this short story as it helps to increase the knowledge of each character. The son, for instance, has a very aggressive tone as the reader may expect from a young frustrated man, an example of that is â€Å"I would like to slap his face and make a man out of him†.

Biocon †Case Assignment Questions Essay

1. Assuming Biocon receives approval for BIOMAb, should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. If Biocon receives approval for BIOMAb, the management team will need to carefully consider what the best course of action is moving forward. If the company elects to launch the drug immediately, they will be able to have the first mover advantage, reaching the market before their closest competitor, Erbitux. BIOMAb will also be able to put themselves on the map as they would be the first ever, proprietary drug developed and marked by an Indian firm for Indian patients. The Indian regulatory authorities may also cause a lengthy Phase 3 trial due to their lack of experience with bringing a proprietary drug to market, as evidenced during BIOMAb’s Phase 2 trials. However, even with all of the above listed considerations in mind, Biocon should conduct the phase 3 trials before launching the BIOMAb. BIOMA b is a superior product to Erbitux, as shown in the 100% response rate when combined with chemo and radiotherapy. There are also fewer side affects, a more patient friendly treatment plan, and BIOMAb will be able to offer the drug at a discounted price. Even if BIOMAb is not able to be the first drug to the market, they will be able to make up for those potential loses in the long run. BIOMAb will be entering this marketplace for the first time, and the company will want to enter the market with as strong of a message as possible. BIOMAb is entering this market for the long run, and overcoming any perceptions of shortcuts, lack of quality, or anything less than cutting edge will last well beyond the life of the BIOMAb product. There are only 300 oncologists in this market Biocon cannot afford to miss. While awaiting Phase 3 approval, Biocon can roll out its direct sales force, offering its suite of generic oncology drugs. This waiting period will give the sales force an opportunity to develop roots in the marketplace and to raise awareness of BIOMAb before it is even on the market. The Phase 3 approval process will serve as an advantageous ramp up time so that Biocon is fully prepared to enter the marketplace on better footing with BIOMAb. This time will also enable Biocon to better develop the infrastructure they will need to  optimize its direct distribution channel. Biocon is a new player in bringing a new drug to the market and they will want to ensure that the quality of their product is maintained from the manufacturing floor into the doctor’s office. Assuming that BIOMAb indeed loses its first mover advantage, its value proposition will be its results, which are dependent on properly controlled product. Biocon wants to become a permanent fixture in this market and the company needs to do everything in its power to deliver its value proposition of innovation, quality, and affordability. 1. How big is the current and future market opportunity in BIOMAb? The current market opportunity that Biocon is currently targeting with BIOMAb is composed of the Head and Neck cancer patients within India. More specifically, Biocon is focused, in the short term, on those Head and Neck cancer patients that can afford to pay, estimated at 1,900 patients. These patients will be the ones officially marketed to, but given the Indian’s markets preponderance for using drugs â€Å"off the label†, the unofficial market can be target at all cancer patients in India that currently able to afford treatment, 7,114 patients. Given India’s continued economic growth rate (9% annually) and ever expanding population base (1.4%), all of the preceding numbers are certain to grow in the relatively short term. The compounded impact of these different rates will cause these India based estimates to grow exponentially year over year. In the long run, BIOMAb in India is just the tip of the iceberg. CIMAB and Biocon’s current joint venture is to develop and market the molecule on the Indian subcontinent. If Biocon is able to thoroughly manage and develop all aspects of the supply chain (manufacturing, distribution, sales, marketing, etc), Biocon would have good reason to go back to the negotiating table with CIMAB. The success of CIMAB’s other partner, YM Bioscience, is not guaranteed and there is no reason that Biocon cannot unseat them in the long run. If Biocon is able to achieve this, along with the Phase 3 trials, the worldwide Head and Cancer would be open to the company, to say nothing for the â€Å"off label† prescriptions. Given the worldwide population growth, economic expansion, and aging populations, the long-term market for BIOMAb is practically limitless. 3. Who is the buyer for BIOMAb? What is the decision making unit in this case? What are the benefits that each member of the decision making unit seeks from BIOMAb? The buyer for BIOMAb is (are) the income provider(s) of the family, whose member (s) has (have) been affected by head and neck cancer or another indication, since off-label usage is very common in India. The structure of India’s health care system is such that it is estimated that 95% of BIOMAb’s patients (end users) are going to be self-paying. Therefore, the cost of treatment will be transferred to the earning member of the family. Adult patients have the right to make treatment decisions for themselves, so patients and their families are the decision makers for BIOMAb in this case. As the case states, the oncology doctors are the main influencers, as they diagnose and make ultimate recommendations to their patients as to how extensive the treatment should be. The benefits that each member of the decision making unit (i.e. patients and their families) seeks include BIOMAb’s effectiveness in the treatment of head and neck cancer in conjunction with radio and che motherapy, minimal side-effects (immediate side effects, as well as those that might be associated with long-term use), and drug’s affordability. Should phase-2 trials be conducted by Biocon for other indications, the patients will also want to seek same benefits from the drug for other types of cancer. Based on the information provided in the case, BIOMAb’s effectiveness and minimized side effects are a given. After all, phase-2 trials proved that the tumor was killed 100% of the time when the drug was used in combination with radio and chemotherapy. Moreover, unlike competition, BIOMAb did not produce skin rashes because due to the drug’s unique formula. An important factor will be affordability. Wealth distribution is very uneven in India, and 1/4 of the nation’s population earns less than the government-specified poverty threshold of $0.40/day (Wikipedia). The patients, as well as their doctors, will want to make sure that they can afford to complete treatment to ensure best possible outcome. BIOMAb has a tremendous advantage in this category compared to Erbitux, as it calls for a definite (i.e. six-dose) treatment cycle; total treatment cost can thus be effectively quantified. Another benefit that  patients will be seeking is the ability of BIOMAb’s sales reps to educate them and their families. Although this is not one of the drug’s literal benefits, it will be a crucial factor since patients’ face time with doctors and specialists is very limited in India. Pre-educating end users and their families on the benefits, side effects, and other specifics of the drug will ensure that oncologists’ time with each patient is maximized. 4. Develop a detailed launch plan for BIOMAb. Provide your rationale for the product portfolio, pricing, channel, and communication decisions. Biocon’s launch of BIOMAb is complicated by several factors. The first of these is the lack of phase 3 clinical trials, which would theoretically provide more evidence of the drug’s efficacy and safety on a larger patient pool. This is complicated by the fact that BIOMAb’s competitor comes in the form of a drug called Erbitux, which does have phase 3 trials completed and global acclaim. Biocon’s fear is that if they do not launch before Erbitux, they will lose the first to market advantage they feel necessary to succeed. In this case Biocon should take the time to complete phase 3 clinical trials on the basis of what patients and their families expect from a cancer drug. It was already stated that Erbitux had worldwide acceptance due to having extensive trials not limited to head and neck cancer that proved it was b oth safe and effective. In the eyes of the consumer the single most important concern here is that the drugs are going to work and that death can be avoided. Being first to market has the risk of offering only a temporary advantage until Erbitux actually becomes available. At this point if phase 3 trials are finally completed and the results are not favorable there would be severe consumer backlash and possibly action from the government. Finally, Biocon mentioned being able to appeal to doctor’s via existing relationships in order to get their product sold. Realistically, doctors care more about clinical trials as a means of deciding what drugs to offer. By moving forward with phase 3 trials Biocon would have real data to give these doctor’s the â€Å"hard sell.† The strategy is not just to maximize profit, but build a sustainable brand built on trust and results in the pharmaceutical industry. Building upon that is the question of whether or not to sell generics in addition to BIOMAb and when to sell them. The argument given was that selling generics would give the sales force good experience and at the  same time build a solid revenue base. Biocon should indeed take this route for these very reasons. This will allow them to still bring in revenue while the phase 3 trials of BIOMAb take place. Once the trials are complete, selling them alongside BIOMAb will allow them to capture more of the market when in front of doctors who want to have offerings for price conscious patients. On top of the first two concerns is the issue of price and what impact it would have on both market size due to affordability and perceived quality in comparison to Erbitux. Biocon, after confirmation of the extraordinarily high effectiveness of BIOMAb should charge $6000-7000 per dose or rather whatever would be equivalent to a few steps more than Erbitux. Biocon’s CEO desires to build a brand not based on low price but rather the value provided by the products. The hindrance to this route of course is the Indian cultural perception of what the price should be and the fact that many people cannot afford such cost. However, Biocon is alread y well aware that their effective target market is small so for those people the price is potentially less important. However, Biocon can market the fact that it is a six dose treatment path rather than indefinite dosages like Erbitux so in the long term people save money. Additionally they can get creative here and offer something like Walmart’s layaway program. Patients can agree to pay in equal installments up until their dosing day. On that final day when payment is received they are administered the dose. Payments for the next dose begin and the cycle repeats until the dosage time. Additionally, Biocon is concerned about the sales methodology with regards to going through the usual channels of CFAs, wholesalers, and pharmacies or selling it directly to doctors. By going through the typical channels they have the advantage of reaching more doctors who have existing relationships with certain sellers. In this case though, it would fit more with their overarching strategy to sell direct. The higher cost of the drug would be less apparent when not being sold side by side with competitor drugs through a pharmacy or wholesaler. This would also allow Biocon to sell the generic drugs and BIOMAb side by side as a complete market solution for price conscious people. The savings from not having a middleman can be passed on to the doctors via multi-patient discounts or similar. Finally, the quality of the product could be ensured since BIOMAb requires such delicate handling. This is important for the Biocon brand image moving forward as  there can be no slip ups when it comes to delivering a product critical to treatment of cancer. The direct sales also tie in with overall marketing communication planning since Biocon would not only control distribution of the product, but also the sales communication. Biocon should take this time during sales to educate doctors on the results of the phase 3 trials and provide materials for patients that explain the availability of Biocon reps during their treatment cycles. Biocon reps, as mentioned in the case, should educate the patient on their product and provide other helpful cancer information and family services in the form of support group references, etc. 5. How has Biocon’s strategy and positioning evolved over the years? What role does BIOMAb play in Biocon’s overall strategy? Biocon’s strategy and positioning have greatly evolved over the years. The company started as an enzyme manufacturing company that exported its products from India to the United States and European food processing industry. During this time the company developed an expertise in various fermentation processes. The company soon realized that the global enzyme market was limited to about $1 billion and decided to change its strategy and position itself to compete in the biopharmaceutical market, which was a $10 billion dollar market that was rapidly approaching $80 billion. Biocon was positioned nicely to move into the space and compete in the generic drug sector. They were particularly positioned well to manufacture statins. Statins were a great fit for them because they were small molecules that were easy to manufacture and Biocon already p ossessed the technical capability to do so drawing on its strength in the fermentation process and enzyme manufacturing. This short-term strategy to enter the market focused on developing globally competitive processes that relied on their existing expertise to manufacture drugs whose patents were expiring. After successfully entering into the pharmaceutical market through statins, the company was ready to continue on a growth path and move on to their medium/long term phase by entering into larger molecules in the form of insulin. Again, Biocon identified a large and rapidly growing market where they saw their expertise in fermentation giving them an edge and ability to compete. The results were consistent with their  first direction change and they were again very successful gaining over 10% of the Indian insulin market share. During this phase of their strategy they partnered with Clinigene to conduct clinical trials comparing it to the market leaders. The current phase of Biocom’s strategy is to shift the company’s focus to the development of proprietary drugs. Management again saw that the market they were competing in would soon shrink due to the maturing of the Indian drug market and they would experience enormous price pressure as a result. Their vision for the company was to develop drugs that no other companies had yet succeeded in bringing to market, and in doing so reaping the benefits of the huge payoff. BIOMAb is the essence of the final and long-term stages of Biocon’s overall strategy. They are using their collaborative strategy to partner with CIMAB thus giving Biocon the opportunity to develop and market the molecule. This is a huge step towards the long-term goal of moving the company to a discovery and development focused biotech firm. BIOMAb is very important to this next phase of the company’s growth. In the past they have relied on their expertise and experience carrying over from the enzyme development background. However in this next phase they are entering into uncharted territory and as a result will need to prove they have the capability to adapt their expertise and continue to be successful in areas that are outside of their experience scope. The success of the BIOMAb phase of Biocon’s overall strategy will be key to the future of the company and could indicate that the strategy they have in place will continue to provide the growth and profitability they seek as a biotech firm.

Biocon †Case Assignment Questions Essay

1. Assuming Biocon receives approval for BIOMAb, should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. If Biocon receives approval for BIOMAb, the management team will need to carefully consider what the best course of action is moving forward. If the company elects to launch the drug immediately, they will be able to have the first mover advantage, reaching the market before their closest competitor, Erbitux. BIOMAb will also be able to put themselves on the map as they would be the first ever, proprietary drug developed and marked by an Indian firm for Indian patients. The Indian regulatory authorities may also cause a lengthy Phase 3 trial due to their lack of experience with bringing a proprietary drug to market, as evidenced during BIOMAb’s Phase 2 trials. However, even with all of the above listed considerations in mind, Biocon should conduct the phase 3 trials before launching the BIOMAb. BIOMA b is a superior product to Erbitux, as shown in the 100% response rate when combined with chemo and radiotherapy. There are also fewer side affects, a more patient friendly treatment plan, and BIOMAb will be able to offer the drug at a discounted price. Even if BIOMAb is not able to be the first drug to the market, they will be able to make up for those potential loses in the long run. BIOMAb will be entering this marketplace for the first time, and the company will want to enter the market with as strong of a message as possible. BIOMAb is entering this market for the long run, and overcoming any perceptions of shortcuts, lack of quality, or anything less than cutting edge will last well beyond the life of the BIOMAb product. There are only 300 oncologists in this market Biocon cannot afford to miss. While awaiting Phase 3 approval, Biocon can roll out its direct sales force, offering its suite of generic oncology drugs. This waiting period will give the sales force an opportunity to develop roots in the marketplace and to raise awareness of BIOMAb before it is even on the market. The Phase 3 approval process will serve as an advantageous ramp up time so that Biocon is fully prepared to enter the marketplace on better footing with BIOMAb. This time will also enable Biocon to better develop the infrastructure they will need to  optimize its direct distribution channel. Biocon is a new player in bringing a new drug to the market and they will want to ensure that the quality of their product is maintained from the manufacturing floor into the doctor’s office. Assuming that BIOMAb indeed loses its first mover advantage, its value proposition will be its results, which are dependent on properly controlled product. Biocon wants to become a permanent fixture in this market and the company needs to do everything in its power to deliver its value proposition of innovation, quality, and affordability. 1. How big is the current and future market opportunity in BIOMAb? The current market opportunity that Biocon is currently targeting with BIOMAb is composed of the Head and Neck cancer patients within India. More specifically, Biocon is focused, in the short term, on those Head and Neck cancer patients that can afford to pay, estimated at 1,900 patients. These patients will be the ones officially marketed to, but given the Indian’s markets preponderance for using drugs â€Å"off the label†, the unofficial market can be target at all cancer patients in India that currently able to afford treatment, 7,114 patients. Given India’s continued economic growth rate (9% annually) and ever expanding population base (1.4%), all of the preceding numbers are certain to grow in the relatively short term. The compounded impact of these different rates will cause these India based estimates to grow exponentially year over year. In the long run, BIOMAb in India is just the tip of the iceberg. CIMAB and Biocon’s current joint venture is to develop and market the molecule on the Indian subcontinent. If Biocon is able to thoroughly manage and develop all aspects of the supply chain (manufacturing, distribution, sales, marketing, etc), Biocon would have good reason to go back to the negotiating table with CIMAB. The success of CIMAB’s other partner, YM Bioscience, is not guaranteed and there is no reason that Biocon cannot unseat them in the long run. If Biocon is able to achieve this, along with the Phase 3 trials, the worldwide Head and Cancer would be open to the company, to say nothing for the â€Å"off label† prescriptions. Given the worldwide population growth, economic expansion, and aging populations, the long-term market for BIOMAb is practically limitless. 3. Who is the buyer for BIOMAb? What is the decision making unit in this case? What are the benefits that each member of the decision making unit seeks from BIOMAb? The buyer for BIOMAb is (are) the income provider(s) of the family, whose member (s) has (have) been affected by head and neck cancer or another indication, since off-label usage is very common in India. The structure of India’s health care system is such that it is estimated that 95% of BIOMAb’s patients (end users) are going to be self-paying. Therefore, the cost of treatment will be transferred to the earning member of the family. Adult patients have the right to make treatment decisions for themselves, so patients and their families are the decision makers for BIOMAb in this case. As the case states, the oncology doctors are the main influencers, as they diagnose and make ultimate recommendations to their patients as to how extensive the treatment should be. The benefits that each member of the decision making unit (i.e. patients and their families) seeks include BIOMAb’s effectiveness in the treatment of head and neck cancer in conjunction with radio and che motherapy, minimal side-effects (immediate side effects, as well as those that might be associated with long-term use), and drug’s affordability. Should phase-2 trials be conducted by Biocon for other indications, the patients will also want to seek same benefits from the drug for other types of cancer. Based on the information provided in the case, BIOMAb’s effectiveness and minimized side effects are a given. After all, phase-2 trials proved that the tumor was killed 100% of the time when the drug was used in combination with radio and chemotherapy. Moreover, unlike competition, BIOMAb did not produce skin rashes because due to the drug’s unique formula. An important factor will be affordability. Wealth distribution is very uneven in India, and 1/4 of the nation’s population earns less than the government-specified poverty threshold of $0.40/day (Wikipedia). The patients, as well as their doctors, will want to make sure that they can afford to complete treatment to ensure best possible outcome. BIOMAb has a tremendous advantage in this category compared to Erbitux, as it calls for a definite (i.e. six-dose) treatment cycle; total treatment cost can thus be effectively quantified. Another benefit that  patients will be seeking is the ability of BIOMAb’s sales reps to educate them and their families. Although this is not one of the drug’s literal benefits, it will be a crucial factor since patients’ face time with doctors and specialists is very limited in India. Pre-educating end users and their families on the benefits, side effects, and other specifics of the drug will ensure that oncologists’ time with each patient is maximized. 4. Develop a detailed launch plan for BIOMAb. Provide your rationale for the product portfolio, pricing, channel, and communication decisions. Biocon’s launch of BIOMAb is complicated by several factors. The first of these is the lack of phase 3 clinical trials, which would theoretically provide more evidence of the drug’s efficacy and safety on a larger patient pool. This is complicated by the fact that BIOMAb’s competitor comes in the form of a drug called Erbitux, which does have phase 3 trials completed and global acclaim. Biocon’s fear is that if they do not launch before Erbitux, they will lose the first to market advantage they feel necessary to succeed. In this case Biocon should take the time to complete phase 3 clinical trials on the basis of what patients and their families expect from a cancer drug. It was already stated that Erbitux had worldwide acceptance due to having extensive trials not limited to head and neck cancer that proved it was b oth safe and effective. In the eyes of the consumer the single most important concern here is that the drugs are going to work and that death can be avoided. Being first to market has the risk of offering only a temporary advantage until Erbitux actually becomes available. At this point if phase 3 trials are finally completed and the results are not favorable there would be severe consumer backlash and possibly action from the government. Finally, Biocon mentioned being able to appeal to doctor’s via existing relationships in order to get their product sold. Realistically, doctors care more about clinical trials as a means of deciding what drugs to offer. By moving forward with phase 3 trials Biocon would have real data to give these doctor’s the â€Å"hard sell.† The strategy is not just to maximize profit, but build a sustainable brand built on trust and results in the pharmaceutical industry. Building upon that is the question of whether or not to sell generics in addition to BIOMAb and when to sell them. The argument given was that selling generics would give the sales force good experience and at the  same time build a solid revenue base. Biocon should indeed take this route for these very reasons. This will allow them to still bring in revenue while the phase 3 trials of BIOMAb take place. Once the trials are complete, selling them alongside BIOMAb will allow them to capture more of the market when in front of doctors who want to have offerings for price conscious patients. On top of the first two concerns is the issue of price and what impact it would have on both market size due to affordability and perceived quality in comparison to Erbitux. Biocon, after confirmation of the extraordinarily high effectiveness of BIOMAb should charge $6000-7000 per dose or rather whatever would be equivalent to a few steps more than Erbitux. Biocon’s CEO desires to build a brand not based on low price but rather the value provided by the products. The hindrance to this route of course is the Indian cultural perception of what the price should be and the fact that many people cannot afford such cost. However, Biocon is alread y well aware that their effective target market is small so for those people the price is potentially less important. However, Biocon can market the fact that it is a six dose treatment path rather than indefinite dosages like Erbitux so in the long term people save money. Additionally they can get creative here and offer something like Walmart’s layaway program. Patients can agree to pay in equal installments up until their dosing day. On that final day when payment is received they are administered the dose. Payments for the next dose begin and the cycle repeats until the dosage time. Additionally, Biocon is concerned about the sales methodology with regards to going through the usual channels of CFAs, wholesalers, and pharmacies or selling it directly to doctors. By going through the typical channels they have the advantage of reaching more doctors who have existing relationships with certain sellers. In this case though, it would fit more with their overarching strategy to sell direct. The higher cost of the drug would be less apparent when not being sold side by side with competitor drugs through a pharmacy or wholesaler. This would also allow Biocon to sell the generic drugs and BIOMAb side by side as a complete market solution for price conscious people. The savings from not having a middleman can be passed on to the doctors via multi-patient discounts or similar. Finally, the quality of the product could be ensured since BIOMAb requires such delicate handling. This is important for the Biocon brand image moving forward as  there can be no slip ups when it comes to delivering a product critical to treatment of cancer. The direct sales also tie in with overall marketing communication planning since Biocon would not only control distribution of the product, but also the sales communication. Biocon should take this time during sales to educate doctors on the results of the phase 3 trials and provide materials for patients that explain the availability of Biocon reps during their treatment cycles. Biocon reps, as mentioned in the case, should educate the patient on their product and provide other helpful cancer information and family services in the form of support group references, etc. 5. How has Biocon’s strategy and positioning evolved over the years? What role does BIOMAb play in Biocon’s overall strategy? Biocon’s strategy and positioning have greatly evolved over the years. The company started as an enzyme manufacturing company that exported its products from India to the United States and European food processing industry. During this time the company developed an expertise in various fermentation processes. The company soon realized that the global enzyme market was limited to about $1 billion and decided to change its strategy and position itself to compete in the biopharmaceutical market, which was a $10 billion dollar market that was rapidly approaching $80 billion. Biocon was positioned nicely to move into the space and compete in the generic drug sector. They were particularly positioned well to manufacture statins. Statins were a great fit for them because they were small molecules that were easy to manufacture and Biocon already p ossessed the technical capability to do so drawing on its strength in the fermentation process and enzyme manufacturing. This short-term strategy to enter the market focused on developing globally competitive processes that relied on their existing expertise to manufacture drugs whose patents were expiring. After successfully entering into the pharmaceutical market through statins, the company was ready to continue on a growth path and move on to their medium/long term phase by entering into larger molecules in the form of insulin. Again, Biocon identified a large and rapidly growing market where they saw their expertise in fermentation giving them an edge and ability to compete. The results were consistent with their  first direction change and they were again very successful gaining over 10% of the Indian insulin market share. During this phase of their strategy they partnered with Clinigene to conduct clinical trials comparing it to the market leaders. The current phase of Biocom’s strategy is to shift the company’s focus to the development of proprietary drugs. Management again saw that the market they were competing in would soon shrink due to the maturing of the Indian drug market and they would experience enormous price pressure as a result. Their vision for the company was to develop drugs that no other companies had yet succeeded in bringing to market, and in doing so reaping the benefits of the huge payoff. BIOMAb is the essence of the final and long-term stages of Biocon’s overall strategy. They are using their collaborative strategy to partner with CIMAB thus giving Biocon the opportunity to develop and market the molecule. This is a huge step towards the long-term goal of moving the company to a discovery and development focused biotech firm. BIOMAb is very important to this next phase of the company’s growth. In the past they have relied on their expertise and experience carrying over from the enzyme development background. However in this next phase they are entering into uncharted territory and as a result will need to prove they have the capability to adapt their expertise and continue to be successful in areas that are outside of their experience scope. The success of the BIOMAb phase of Biocon’s overall strategy will be key to the future of the company and could indicate that the strategy they have in place will continue to provide the growth and profitability they seek as a biotech firm.

When and How to Use Brackets

When and How to Use Brackets When and How to Use Brackets When and How to Use Brackets By Maeve Maddox Reader John B. Moss asks if there are guidelines for the use of brackets. There are indeed. Academic style guides such as the MLA Handbook for Writers of Research Papers go into such matters at great length. The most common use of brackets is to enclose explanatory matter that one adds in editing the work of another writer. They indicate that some kind of alteration has been made in the original text. 1. In quoting a passage it is often necessary to insert information that was provided elsewhere in the original text: I dont care what he [Poe] meant by it, the line sounds great but makes no sense. 2. Sometimes a word in the quotation is archaic or used in a sense that may not be familiar to the intended reader so the editor may wish to provide an explanation in brackets: Paul said he was let [hindered] hitherto. In this episode of C.S.I. her character says Gimme some bling [gaudy jewelery]. 3. Sometimes its necessary to change the original capitalization or provide a word in order to make a quotation fit grammatically into the new text: Original: He was an out-spoken old curmudgeon. Quoted form: According to Joness biographer, [h]e was an out-spoken old curmudgeon. 4. Sometimes brackets are used to enclose the dots that indicate missing words. The usual way to indicate that some words have been left out (an ellipsis) is to mark the spot with three dots (). Original: It little profits that an idle king, By this still hearth, among these barren crags, Matchd with an aged wife, I mete and dole Unequal laws unto a savage race Incorporated quotation: According to Ulysses in Tennysons poem, it little profitsan idle kingtomete and dole unequal laws unto a savage race. Some (but not all) academic writers would enclose the dots in a quotation in brackets: According to Ulysses in Tennysons poem, it little profits[]an idle king[]to[]mete and dole unequal laws unto a savage race. Another use of brackets Brackets can be used in the context of ones own writing when more than one thing needs to be set apart. For example: Watching a popular actor who usually plays good characters play a villain (like Tom Hanks in Road to Perdition [2002]) has a negative effect on many movie-goers. Want to improve your English in five minutes a day? Get a subscription and start receiving our writing tips and exercises daily! Keep learning! Browse the Punctuation category, check our popular posts, or choose a related post below:12 Signs and Symbols You Should Know10 Types of TransitionsWhat’s the Best Way to Refer to a Romantic Partner?

Much Ado about nothing Essays

Much Ado about nothing Essays Much Ado about nothing Paper Much Ado about nothing Paper Essay Topic: Much Ado about Nothing Much Ado About Nothing was written in 1600 by William Shakespeare. The play is set in Messina, Sicily however it shows typical English comedy characteristics for that time. I find this unusual because not many people travelled far from home. Relationships are shown in various ways throughout the play using themes such as love, romance and patriarchal society. The main relationships which are portrayed are between Hero and Claudio and Beatrice and Benedick. Act two scene one is the masked ball. Conversations take place between a number of couples; this makes the scene seem lively and gives a sense of movement. The character Beatrice is attracted to Benedick. However Shakespeare confuses the audience by having Beatrice pass insults to Benedick, masking her real feelings. Beatrice says to Benedick why he is the Princes jester, a very dull fool; only his gift is in devising impossible slanders. Beatrice is teasing Benedick so that her real feelings towards him are concealed. Don John appears to deliberately try to cause problems in the relationship between Hero and Claudio by claiming how canst thou cross this marriage? Don John is showing his distaste for the marriage his brother arranged. This is because Don John is jealous of his brothers higher status and success. Because he is illegitimate, he does what he can to cause problems for his brother and his friends. Act four scene one, the wedding scene, starts with the marriage of Hero and Claudio, who are genuinely in love. However the wedding does not go as planned as Claudio was tricked by Don John into believing Hero had not been faithful the previous night. Claudio reveals his cruel side by making this fact known in public at the wedding, disgracing Hero and her family. He adds further insult by saying give not this rotten orange to your friend; this is a metaphor claiming Hero is rotten on the inside but outwardly she appears sweet which adds to the continuing theme of appearance versus reality. Claudio also calls her an approved wanton which literally means prostitute. Hero attempts to reclaim her innocence by answering I talked with no man at that hour, my lord but otherwise does not defend herself. This is in keeping with the behaviour of women at that time who were expected to be passive and submissive. Leonato chooses to believe the accusations; he shows no mercy for his own child and wishes her dead by stating death is the fairest cover for her shame that may be wished for. This shows that father/daughter relationships werent as relaxed as they are now as the daughter had everything planned for her by the father. Also the quote shows that language was much more dramatic in Shakespearian times. This also reminds us of Shakespeares Romeo Juliet where Juliets father Lord Capulet was quick to disown her as soon as she went against his word. Further on in act four Benedick says to Beatrice I do love nothing in the world so well as you and eventually despite her protests against marriage and relationships, Beatrice acknowledges her concealed love for Benedick by saying I love you with so much of my heart that none is left to protest. Beatrice then demands that Benedick Kill Claudio in revenge for the shame inflicted upon her cousin Hero. When Benedick refuses she claims that he does not love her and that they can only be friends. Beatrice was testing Benedick to find out how far he was willing to go to prove his love for her. This also shows the extent people had to go to in those days to uphold family honour. Also in this scene Beatrice declares O God that I were a man! I would eat his heart in the market place. The quotation shows her distaste for Claudio and what he did to her cousin and that she wants Claudio to be humiliated publicly just like Hero. The quote also shows that it was not considered a womans place to disagree with a man. She repeats several times her wish to be a man which highlights the lack of power women had. Shakespeare has shown that in Much Ado About Nothing the play has a moral context in which women were required to be maidens at marriage. Shakespeare has used some poetic language, particularly in declarations of love between characters; he does this by changing between verse and prose. There is also irony and humour in the form of Beatrices disapproval of marriage, which completely changes when the relationship between her and Benedick grows. Show preview only The above preview is unformatted text This student written piece of work is one of many that can be found in our GCSE Other Poets section. Download this essay Print Save Top Heres what a star student thought of this essay 4 star(s)

Global Context Of Modern Business Essay Example | Topics and Well Written Essays - 2500 words

Global Context Of Modern Business - Essay Example Globalization is increasing the interdependence among the economies. However, the developing countries are enjoying increasing access to markets of developed economy that facilitates easy transfer of technology and capital movements but it is increasing the inequality among the global economies. The negative aspect of globalization is that instability or downturn in any major economies of the world results in the downturn of the global economy as a whole. This is because the domestic economic developments of countries determined not only by the domestic policies but also by international policies and economic situations. Thus in order to implement any developmental policies not only the domestic impact but also the global impact of that policy has to be considered (Balakrishnan, 2004). Moreover globalization may create more unemployment problems because of increasing firm closure and lower wages of the employed. This is because increasing competition often wipes out the small firms t hat are incapable to compete and secondly more use of modern and advanced technology in production adversely affects some companies manufacturing unimproved machineries (Moffatt, 2011). There is coexistence of both positive and negative impacts in every aspects and globalization is no exception. Thus to study modern business in the global context the most important issue that need to be considered is the impact of the global financial crisis which triggered the global economy during 2007. Globalization has increased the financial movement across countries because of lucid monetary controls and regulations and thus financial globalization is associated with the financial crisis of 2007. The paper discusses the nature and impact of the crisis on the countries’ business environment. The Financial crisis – nature and impact The people of topical times are still living with the recollections of the Great Depression of the 30s. There has been no record of economic avalanche of same scale and duration till this date, but the recent global financial crisis is not less important. The economic recession of 2007 has already found its position in the records of American politics. It is less brutal than the great depression of 1929 but has thrown its shadows on worldwide politics and economy. The crisis of 2007 will be considered as a short follow-up to the 1929 depression. The government policies and concern have been held responsible once again for the financial crisis – â€Å"Americans have lost faith not only in the [Bush] administration, but in its economic philosophy: a new corporate welfarism masquerading behind free-market ideology; another version of trickle-down economics, where the hundreds of billions to Wall Street that caused the problem were supposed to somehow trickle down to help ordinary Americans. Trickle-down hasn’t been working well in America over the past eight years.† (Stiglitz, October 2008) The social, political and economic perils of the global financial crisis of 2007 will continue to persist for another few months. The American government and European Union have thrived for a united effort to counter the recession. It seems like a group action on the part of the national leaders will be more valuable in restoring the backbone. The world has altered a lot since the Second World War. The harmony among different nations and their joint effort to expand the world as a whole had come

Medical Law and Ethics Essay Example | Topics and Well Written Essays - 750 words - 1

Medical Law and Ethics - Essay Example It is thus clear that Jerry is not qualified to carry out the supply to the patient (Baxter & Brennan, 2005). The only qualification required lawfully to dispense medication to any patient or any medical situation in and outside the healthcare setting is a license to do so. With or with no medical training, it is against the law to refill a medical script with no the appropriate license. There are several factors as to why Jerry should not refill the prescription. Firstly, valium is not an anti-depressant as the patient claims. In fact, this drug can do more harm to depression. Secondly, Jerry has no authority to recommend medications (Herring, 2006). Each every medication refills ought to be approved by the doctor or another empowered figure at the hospital, finally, the decision on whether the patient needs valium in the course of the flight or not is made by the patient’s physician and not by the patient himself. Even if the medication were required to control high blood pressure, it would make no difference, according to the medical ethics; Jerry is not qualified to issue medical prescriptions. Jerry is supposed to convince the patient that he is not qualified to refill the prescription but is willing to do everything to make sure that he informs the doctor. If the patient were in a critical condition, the right thing would be to make an effort of reaching Dr. Williams for the sake of the emergency with the critical patient’s prescription to be filled in. Once the Doctor is back from the lunch break, Jerry ought to provide the order to him so that it can be filled as soon as possible (Fremgen, 2008). In this case, both the doctor and Jerry are liable for the act of medical negligence. Precisely Jerry would be charged since he is not protected from any charges under the doctrine of respondent superior.